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Abstract
Influenza is one of the most common diseases worldwide, yet the vaccines against
influenza are only 35% effective at protecting against infection. Creating a more effective
vaccine requires an understanding of the foundation and the factors that contribute to a strong
and protective adaptive immune response. T-bet [TBX21] is a transcription factor that plays an
instrumental role in the orchestration of the type 1 immune response, which is the specialized
response used by the immune system for a cell-mediated response against intracellular
pathogens, such as influenza. It has yet to be explored in an influenza setting on the role T-bet in
the production of antibodies. The aim of this study is to understand T-bet’s role in production of
antibody isotypes and identify whether expression of T-bet is more important for antibody
production in T cells or B cells. We expected T-bet knockout (KO) mice to have IgG2a and that
T-bet expression would be more important in T cells for antibody production. An enzyme-linked
immunosorbent assay (ELISA) was used to measure the amount of virus-specific antibody in Tbet KO versus wild type (WT) mice infected with influenza. The results show that the T-bet KO
and WT mice have relatively the same amount of IgG and IgG1, but the T-bet KO have a
significantly lower level of IgG2a, confirming T-bet’s importance for its production. To
distinguish the importance of T-bet expression while T-bet expression in T cells was constant, a
model was developed to allow us to control expression of T-bet in B cells. The results however
were inconclusive, and the experiment will have to be repeated to make a firm conclusion on the
roles of lymphocytes in the control of IgG isotypes. Overall, these results indicate that the
manipulation of T-bet expression can be used as a vector to control IgG antibody levels, which
holds potential for the improvement of vaccines.
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BACKGROUND
Influenza and Vaccination
Influenza A virus (IAV), commonly called the flu, is one of the most common diseases
globally, with nearly 5 million severe cases and 500,000 deaths per year [1]. With the virus
constantly mutating, vaccines must be administered during each flu season. The vaccines are also
inefficient: aside from the constant mutations, scientists must determine the strain that is causing
the epidemic. Vaccine effectiveness for the past three years averages only 35% [2-5].
Understanding the immune response against IAV, specifically the isotypes of antibody being
produced and the effectiveness of each, can help produce a more protective vaccine. Not only
would this prevent millions of flu cases and deaths every year, in both developed and developing
nations, but the money this would save in both healthcare and the business industries is
significant. On an even larger scale, understanding the factors that result in and effect the
production and efficacy of adaptive immunity has greater implications in the treatment of other
diseases and autoimmune disorders.
Vaccination is based on the understanding that upon being infected by, and clearing a
pathogen, the body will be less susceptible to reinfection by that same pathogen. The
immunology behind this is the creation of memory cells by the adaptive immune system that are
specific for the infecting pathogen, and upon reinfection, allow for an immune response that is
faster and stronger than before, thereby offering protection against it [4]. Therefore, it is not
surprising that creating a safe and effective vaccine is one of the best ways to mitigate infection
by even the deadliest and virulent of pathogens.
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IAV Variants
The variants of IAV are based on the different subtypes of hemagglutinin (HA) and
neuraminidase (NA) that the virus displays. These glycoproteins have different functions:
hemagglutinin allows the IAV to bind to the target cell and neuraminidase helps the virus spread
[5]. The differences in these proteins is what allows for a heterosubtypic challenge, as the
antibodies produced against one strain are not protective against another strain. The variants used
in this experiment include PR8 (H1N1), A/Phil (H3N2), and A/Alaska (H3N2). Both PR8 and
A/Phil are virulent strains of IAV whereas A/Alaska is a vaccination strain, which is important to
note as this may lend translation of the results to humans, in terms of assessing how T-bet
expression may impact vaccine efficacy.

Immune System
There are two types of defense systems used by the body for protection, innate and
adaptive. In the case of a pathogen bypassing the innate immune system, the adaptive immune
system, comprised of T cells, B cells, and antibodies, is activated to generate a more sustained
and specific immune response. It is also important to note that the innate immune response is
required for an adaptive response, as the innate response sets the stage for the adaptive immune
system. T cells are lymphocytes that develop in the thymus, where they produce an antigenspecific T cell receptor (TCR) through gene rearrangement. They then travel through the blood
and lymphatics in search of their specific antigen, which, upon binding, will allow them to
mature and begin their various effector functions. There are two main types of T cells consisting
of CD8+ cytotoxic T cells, which target and kill infected cells, and CD4+ T helper (Th) cells,
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which facilitate and optimize the immune response by stimulating other immune cells [6]. Naïve
CD4+ T cells differentiate into different subtypes, as a result of specific cytokines, each with a
specialized role, generally: Th1 protects against intracellular pathogens, Th2 and Th17 defend
against extracellular pathogens, T-follicular helper (Tfh) provides help to B cells, and periphery
T regulatory (pTreg) prevents inflammation-mediated injury to tissue [7-11].
B cells are lymphocytes that develop in the bone marrow, and also have a specific B cell
receptor (BCR) produced by gene rearrangement. Upon finding their specific antigen, B cells
will differentiate into plasma cells and produce large soluble amounts of their BCR, referred to
as antibodies. These antibodies will bind to their specific antigen and allow for neutralization,
opsonization for phagocytosis, or direct killing via protein complement [9].

Immunoglobulin Isotypes
Immunoglobulins, more commonly referred to as antibodies, are proteins secreted by B
cells which bind to a specific antigen. An antibody consists of a variable region (Fv), which is the
antigen-binding portion, and the constant region (Fc), which determines the class of the antibody
[12]. Each antibody isotype has a specific role in the immune response: IgG is the most abundant
antibody, has a high affinity for its antigen, and is characteristic of a secondary immune
response, IgM is a pentamer found during the primary immune response with a low affinity but
high avidity, IgA is a monomer in blood or a dimer found in mucous secretions, IgE is a
monomer that protects against parasites and plays a role in allergic reactions, IgD is found on B
cells, but its function has yet to be determined. As previously mentioned, the initial antibody
produced is IgM, but as the infection progresses, and upon the interaction of various signaling
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molecules, the plasma cell will undergo class switching, where the Fc region in the gene will be
recombined to express a different class with different effector functions [13].
IgG also has several subtypes, the most abundant of which are IgG1 and IgG2a, which
generally respond to proteins and polysaccharides respectively [14]. Since they each have
specific functions, the relative amounts of each have often been used as markers of what type of
immune response is occurring. IgG1 is associated with type 2 immunity while IgG2a is indicative
of type 1 immunity. IgG2a also has more Fc receptor-mediated reactions, especially with protein
complement activation, while IgG1 has weaker Fc interactions.

Antibodies in IAV
Since IAV is an intracellular pathogen, type 1 immunity is employed against it. The
antibodies specific against IAV are primarily of the IgG isotype, but of greater interest are the
subtypes in play. Being a type 1 immune response, we would expect IgG2a to be more prevalent.
An interesting follow-up to this assumption is that the literature has shown that higher levels of
IgG2a were associated with greater clearance of and protection against IAV [9]. These findings
are significant in relation to T-bet because of T-bet’s role in the class switching of B cells to the
IgG2a subtype. This is even more important in the context of producing a more effective
vaccination against IAV.

Immune Response Regulation
Upon encountering a pathogen, the body can utilize a variety of immune responses for
protection. The type of immune response triggered is largely based off how the pathogen infects:
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intracellular pathogens trigger a type 1 response and extracellular pathogens trigger a type 2
response [8]. With the focus of this paper being IAV, we are most interested in exploring type 1
immunity. Briefly, a type 1 immune response is coordinated by a division of T cells referred to
as T helper 1 cells, which secrete the cytokines interleukin (IL) 2 and interferon-gamma (IFN-y),
among others, to generate a cell-mediated response that involves phagocytes, cytotoxic T cells,
and cytokines protecting against an intracellular pathogen [15]. Type 1 immunity is considered
protective, and is characterized by CD4+ Th1 cells, IFN-y, and CD8+ T cells, which protect by
triggering phagocytosis [9].

T-bet and Type 1 Immunity
T-bet is a T-box transcription factor, encoded by TBX21, which serves as a master
regulator of Th1 differentiation, but its significance extends beyond a regulator [6]. T-bet plays a
role in both the innate and adaptive immune systems, being necessary for the development and
function of a variety of immune cells, including natural killer cells, dendritic cells, B cells, and
CD8+ T cells [16,17]. Even more interesting is T-bet’s role in the creation and maintenance of
memory T and B cells. Together with eomesodermin (EOMES), T-bet determines the fate of T
cells; EOMES promotes memory formation while T-bet promotes terminal differentiation.
[12,18-21]. EOMES is also a T-box transcription factor, but unlike T-bet, it is not greatly
expressed in CD4+ T cells. Rather it is highly expressed in CD8+ T cells and has been associated
with the anti-cancer properties of CD8+ cells [6]. It also plays a role in the migration of these
IgG2a B cells to inflammatory sites and is necessary for the survival of IgG2a memory B cells
[7,22].
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Thus far, literature strongly suggests that help provided by the CD4 T cell subtype is
responsible for the antibody switching of B cells [6]. Recent studies have also suggested that the
different antibody subtypes may have varying degrees of efficacy against IAV. It is known that
the different Fc regions of antibodies have different effector functions, this study sought to
explore their contributions by measuring the amount of neutralizing antibodies formed against
hemagglutinin. Researchers found that there were different levels of IgG1 and IgG2a produced in
response to different elements of IAV, in addition to correlating a higher level of IgG2a with
better clearance and protection against IAV [9]. The differences in antibody efficacy is not
limited to IAV, literature exploring immune responses to Schistosoma mansoni, Leishmania
tropica, and cancer each found an IgG subtype to be more effective at conferring immunity [79]. This information brings up a very important point with regards to IAV vaccination: if
different antibody isotypes have been shown to have different degrees of protection, and T-bet
plays a role in antibody class switching [23], then understanding T-bet’s role within an IAV
setting holds great potential for strengthening the immune response and preventing the seasonal
IAV epidemic. If one antibody isotype is proven more effective, vaccines can be created to
induce a greater production of that isotype and thus offer greater protection.

T-bet and Antibody production
While antibodies are not the hallmark of a type 1 immune response, they are still
produced in substantial amounts [15]. The most common antibody found in circulation is the IgG
isotype, which is also the isotype that targets and neutralizes IAV [15]. It is unknown how T-bet
affects antibody production in an influenza setting, although literature has suggested that T-bet
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expression drives the generation of the IgG2a isotype, while Th2 responses promote the
generation of the isotype IgG [6]. Thus, it is expected that the absence of T-bet will result in
decreased levels of IgG2a. A follow-up question to this assumption is whether the total levels of
IgG are lowered, or if another isotype is produced in greater amounts. Since T-bet appears to
only induce class switching to IgG2a, it is expected that the total amount of IgG will remain the
same in the presence or absence of T-bet, and the IgG1 will make up for the lack of IgG2a. Recent
studies have suggested that the different subtypes may have varying degrees of efficacy against
IAV [24]. Exploring these differences will help us understand T-bet’s role in the production of
influenza-specific antibody. This information can then serve as the basis to produce a more
efficient vaccine against IAV. If we can understand what isotypes offer the most protection
against IAV, we can adjust vaccines to help produce the most effective immune response.

Expression of T-bet
For B cells to mount an effective immune response, they require help from T cells. There
are a variety of categories that T cells offer help in, but the simplest is inducing B cell
proliferation, allowing the B cells to differentiate into plasma cells and memory B cells [23-26].
T-bet is not exclusive to T cells, which leads to the question whether the differences in antibody
production are attributable to T-bet expression in T cells or B cells. It cannot be assumed that
expression is more important in T cells simply because of the help that they provide to B cells.
Literature has suggested that T-bet expression in B cells is vital for production of IgG2a [23].
Importance can only be determined by knocking out T-bet expression in either T cells or B cells
and comparing the antibody production. Specifically, we would explore the amount of IgG2a and,
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using the results of T-bet’s impact of antibody production, determine in which cell the
expression of T-bet offers the most protection against IAV. As aforementioned, studies have
shown that the help provided by CD4 T cells is most likely responsible for class switching, thus
it is plausible to assume that T-bet expression is more significant in T cells.

Aims
In this study we seek to:
Aim 1: Explore the effect of T-bet expression on the quantity and isotype of flu-specific
antibodies produced during a primary and secondary influenza infection.
Aim 2: Determine whether T-bet expression in B cell or T cells is more important for the
production of flu-specific antibody.
We expect that T-bet knockout (KO) mice will have less IgG2a and that T-bet expression
will be more important in T cells for antibody production.
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METHODS
Mice
WT or T-bet KO mice on a C57BL/6 background were used to obtain the serum samples.
The mice used were between 8-12 weeks of age.

Virus
The virus variants used in this experiment include PR8 (H1N1), A/Phil (H3N2), and
A/Alaska (H3N2).

Infection and Harvesting
For the IAV infections, the mice were anesthetized using isoflurane, and were then
intranasally infected with 50µL virus diluted in phosphate buffered saline (PBS) at a varying
priming dosage of 0.2 - 0.5 lethal dose 50% (LD50). After the mice returned to their preinfection weight, they were then challenged with a supra-lethal dose of a heterosubtypic virus in
the range of 50LD50 - 200LD50.
Because most of the serum samples were taken after the heterosubtypic challenge, the
blood could be harvested via cardiac puncture, where the mice are anesthetized with isoflurane
and a 23-25-gauge needle is used puncture a ventricle and draw blood. For the set of Day 45 preheterosubtypic challenge mice, a submandibular puncture was performed, where the
submandibular vein is pierced with a lancet and blood collected. To separate the serum from the
plasma, the harvested blood was centrifuged at 1000-2000g for 10 minutes, and the serum was
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pipetted out. All animal procedures were performed in accordance with the University of Central
Florida’s Animal Care and Use guidelines.

Enzyme Linked Immunosorbent Assay (ELISA)
An indirect ELISA was used to analyze the serum samples. A 96-well ELISA plate was
coated first with a 1:100 dilution of PR8 IAV, accounting for a blank, conjugate blank, and
negative controls, and allowed to incubate for a day. The plate was then washed three times with
phosphate buffered saline with tween 20 (PBST). Serum from infected mice was then serially
diluted in a flat-well plate, transferred to the ELISA plate, allowed to incubate for a day, washed
three times with PBST, and then the secondary antibody was added in a 1:2000 dilution to each
well and allowed to incubate for three hours. The secondary antibody used was the “anti” of the
isotype of interest, which was also linked to a horseradish peroxidase (HRP) enzyme. After
washing again three times with PBST, the binding in each well was determined using ophenylenediamine (OPD) with acid stop (25% H2SO4) and the optical density was determined
using a plate reader set at 492nm. To determine the endpoint, the lower limit of detection was set
to be twice the mean of the conjugate blank wells.
Two different analyses were performed on the data collected, the first and more direct
being the absorbance graph. The absorbance of the two groups (T-bet KO or chimeras) was
compared to that of the WT throughout the dilution, and based on those values, it could be
concluded whether a significant difference existed between the said group and the WT mice. If
both samples reached an endpoint, set based on the conjugate blanks, an analysis of the endpoint
titers was performed. Using endpoint titers offers a more specific understanding of how much
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antibody was present. The main isotypes that were analyzed were IgG, IgG1, and IgG2a. There
were a few analyses run on the presence of IgA, but the main focus was on the isotypes of IgG,
as these are indicative of the adaptive immune response and thus is most important in the context
of vaccination.
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RESULTS
Serum Samples
In exploring the differences in antibody production, serum samples were acquired from
the flu primed T-bet knockout (KO) mice and wild type (WT) mice. As we were interested in
determining the antibody concentrations, the majority of serum samples from the infected mice
were taken well-after the resolution of primary infection, a time period where we were certain
there would be high levels of IgG. Both primary and heterosubtypic infected mice were used for
this experiment, which allowed us to test for levels during both primary and recall conditions.
This experiment looked at mice day 45 of infection and mice at day 6 and day 14 after a
heterosubtypic re-challenge of IAV. A heterosubtypic challenge involves using a different
subtype of a virus, in this case IAV, to illicit an immune response. The initial priming is the basic
infection of the mouse with a virus, the challenge however involves giving a virus that has a
different subtype.
For us to explore the difference in T-bet expression, we would need to have mice that
expressed T-bet in either T cells or B cells, but not both. To achieve this a rather creative
solution was used. We began by utilizing nude mice, which lack a thymus and thus T-cells, and
lethally irradiated them to eliminate all hematopoietic cells and reconstituted them with either
WT or T-bet KO bone marrow, and both groups were given the same WT CD4 T cells. This
allows for the creation of 2mice that have T cells that express T-bet, but the B cells are either KO
or WT for T-bet. This setup allowed for us to determine whether B cell expression of T-bet
significantly impacts antibody production.
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Assay Selection
As we were investigating levels of IAV-specific antibody isotypes in infected mice, the
ELISA was selected as the most appropriate assay, considering its high sensitivity and
specificity. The hemagglutination inhibition (HI) assay was considered, but ultimately the
ELISA was chosen as the assay of choice because of the specificity it offered, and the nature of
the experiment. The HI assay functions by antibody preventing IAV attachment to the red blood
cells, and the level of inhibition is measured. The point of this experiment is to measure the
amount of antibody present in the serum, not necessarily the level that is protective against IAV.
When performing the ELISAs, a goal was to achieve an endpoint titer for each sample, as it
would provide a more specific and accurate measurement, and thus varying dilution factors were
used when creating the serial dilution to achieve an endpoint.

T-bet & Antibody Production: Total IgG
The ELISA assay using anti-IgG was run on 24 mice, and the best data from three
different experiments, each repeated once to ensure accuracy, are presented here. The absorbance
and titer graphs for the Day 45 pre-heterosubtypic challenge sample, primed with PR8 (H1N1),
(Figure 1) compares the relative amount of antibody present in the T-bet KO mice versus WT.
The absorbance and titer data are also shown for mice at Day 14 post-heterosubtypic challenge,
primed with A/Alaska and challenged with PR8 (H1N1), (Figure 2).
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Figure 1: Absorbance (left) and titer (right) graphs for total IgG in Day 45 pre-heterosubtypic challenge mice. Six
mice used in both the T-bet KO group and WT group.
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Figure 2: Absorbance (left) and titer (right) graphs for total IgG in Day 14 post-heterosubtypic challenge mice.
Three mice used in both the T-bet KO group and WT group.

The absorbance data suggests that there little, if any, difference in the total amount of IgG
produced by the T-bet KO or WT mice. This if further supported by the titer data, with the titers
being the same or within error. Also important to note is that although there is a difference
between the data for Day 45 pre-heterosubtypic challenge and Day 14 post-heterosubtypic
challenge data, the trend is the same for the two groups. This shows that T-bet’s control of
antibody production is consistent whether it be a primary or recall condition. This also verifies
14

that the heterosubtypic challenge both was successful and elicits a strong adaptive immune
response earlier than the primary infections, a finding that is congruent with the basic model of
an immune response.
Another twist to this piece of data involves the Day 14 post-heterosubtypic challenge
mice that were primed with the A/Alaska vaccination strain. Thus, this helps to draw more
significance and translational application of these findings to humans.

T-bet & Antibody Production: IgG1 & IgG2a
The absorbance and titer graphs for the Day 45 pre-heterosubtypic challenge sample
compare the relative amount of IgG1 (Figure 3) and IgG2a (Figure 5) present in the T-bet KO
mice versus WT. Day 14 post-heterosubtypic challenge absorbance and titer data for IgG1 and
IgG2a are shown in Figure 4 and Figure 6, respectively.
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Figure 3: Absorbance (left) and titer (right) graphs for IgG 1 in Day 45 pre-heterosubtypic challenge mice. Six mice
used in both the T-bet KO group and WT group.
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Figure 4: Absorbance (left) and titer (right) graphs for total IgG1 in Day 14 post-heterosubtypic challenge mice.
Three mice used in both the T-bet KO group and WT group.
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Figure 5: Absorbance (left) and titer (right) graphs for IgG2a in Day 45 pre-heterosubtypic challenge mice. Six mice
used in both the T-bet KO group and WT group.
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Figure 6: Absorbance (left) and titer (right) graphs for IgG 2a in Day 14 post-heterosubtypic challenge mice. Three
mice used in both the T-bet KO group and WT group.

Staring with IgG1, it can be seen, as with the total IgG, that there is little difference
between the amount of IgG1 present in the T-bet KO versus WT mice. However, there is a
significant difference in the absorbance of IgG2a in the T-bet KO and WT mice. The T-bet KO
displayed a substantially lower absorbance and titer for IgG2a, which is a finding consistent with
literature. Since T-bet is responsible for the production and class-switching to the IgG2a isotype,
the knockout of the gene would be expected to have a severe impact on the amount of IgG2a that
is produced.
Another interesting finding from this set of data, is that despite IgG2a being so low in the
T-bet KO mice, the total IgG is nearly the same for the T-bet KO and the WT mice. This means
that there must be some sort of compensation mechanism for the low levels of IgG2a, but it
cannot be the IgG1 because those levels, again, are the same between the T-bet KO and WT
mice. This suggests that there must be another subtype of IgG that is compensating for IgG2a.
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T-bet & Antibody Production: IgA
Another isotype explored in this experiment to a more limited extent was IgA, again
looking at the absorbance and titer of Day 14 post-heterosubtypic challenge T-bet KO versus WT
mice (Figure 7). As expected, there are extremely low levels of IgA in the mice, mainly because
this experiment models an adaptive immune response thus IgG will be the most prominent
antibody. Another reason is that IgA is mainly found as a dimer within secretions, and this
experiment is looking at serum, which will contain small mounts of monomeric IgA that is
secreted into the bloodstream. There is also no difference between the T-bet KO and WT mice,
verifying that the presence of T-bet has no impact on the production of the IgA isotype.
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Figure 7: Absorbance (left) and titer (right) graphs for IgA in Day 14 post-heterosubtypic challenge mice. Three
mice used in both the T-bet KO group and WT group.

T-bet Expression: IgG
The ELISA was also used in the second part of this experiment in exploring the
significance of T-bet expression in T or B cells by using the total bone marrow (BM) chimeras.
There were multiple replicates of chimeras used, but all were primed with PR8 (H1N1) and
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challenged with A/phil (H3N2). The absorbance and titer data for the total IgG is shown in
Figure 8.
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Figure 8: Absorbance (left) and titer (right) graphs for IgG in BM Chimera. Two mice used in the T-bet KO
Chimera and one mouse in WT.

Similar to knocking out T-bet completely, there appears to be no significant difference
between the T-bet KO and WT groups in the total amount of IgG present. This again implies that
if there is a deficiency in one of the IgG isotypes, it is compensated for by another subtype.
There is not much information to draw from the absorbance graph as there are overlapping error
bars, and we cannot state with confidence that one group has a greater amount of antibody. These
overlapping error bars were also present in the replicate, suggesting that it may not be a random
error, although it could be related to the mice themselves (the WT mouse did not have a strong
immune response). If the data is accurate, this suggests that the lack of T-bet expression in B
cells may have actually improved the immune response in terms of antibody levels. However, the
titer data, which offers a more specific quantification, does not show a significant difference. To

19

ensure that we are confident in the difference in total IgG, future studies should replicate this
portion to confirm these trends.

T-bet Expression: IgG1 & IgG2a
We also looked at the absorbance and titers for IgG1 (Figure 9) and IgG2a (Figure 10) in
the BM chimeras.
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Figure 9: Absorbance (left) and titer (right) graphs for IgG 1 in BM Chimera. Two mice used in the T-bet KO
Chimera and one mouse in WT.
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Figure 10: Absorbance (left) and titer (right) graphs for IgG 2a in BM Chimera. Two mice used in the T-bet KO
Chimera and one mouse in WT.

The data for these two subtypes is a bit difficult to draw conclusions from. The titer data
appears to show a significant difference in IgG2a between the T-bet KO and WT mice, but
looking at the absorbance graph, we see that both isotypes have nearly flat absorbances and have
an increase in absorbance at the end of the dilution. This is not how an ELISA absorbance graph
should look like, rather, the graph should have a constant slope down that is indicative of the
serial dilutions that were performed on the sample. It is also worth noting that the other replicates
showed similar trends, which leads us to conclude that there might have been an issue with the
samples rather than a systematic or random error. Sources of these errors will be explored in the
Discussion.
Even though the titer graphs do not appear skewed, those values are generated from the
absorbance chart, which are unreliable to draw conclusions from. Thus this experiment would
need to be repeated to obtain any accurate conclusions.
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DISCUSSION
T-bet is a transcription factor that plays a role in both innate and adaptive immunity, in
addition to being a master regulator of type 1 immunity. T-bet has been shown to affect the class
switching of antibodies, to IgG2a specifically, which is important in the setting of IAV as these
flu specific antibodies are what help the immune system mount a strong and successful immune
response against IAV. In exploring the impact of T-bet on the production of antibody isotypes in
a mouse model of IAV, we discovered that the levels of IgG2a were indeed significantly lower in
the T-bet KO versus the WT, which concurs with literature. Also interesting is that the levels of
total IgG and IgG1 are very nearly the same between the T-bet KO and WT groups. This means
that although the T-bet KO mice might be deficient in the IgG2a isotype, they are not deficient in
the total amount of IgG. This leads to the question of which antibody isotype is making up for
the deficiency in IgG2a, and the answer is not IgG1, because those levels are also the same
between both groups, the answer might be within another isotype of IgG not explored in this
study, such as IgG3 or IgG2b, and can be the focus of future research: exploring what antibody
isotype is higher in T-bet KO and whether it is that isotype that T-bet switches to IgG2a or
whether it is another factor that compensates in the absence of T-bet.
Another important finding of this study is that the heterosubtypic challenge was
successful in that it produced a stronger immune response than the primary infection state, but
also showed the same trends in antibody levels in the T-bet KO mice. In all the experiments and
replicates, the Day 45 pre-heterosubtypic challenge mice showed similar absorbances and titers
to that of the Day 6 and Day 14 post-heterosubtypic challenge mice.
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The experiment from exploring the possible differences in the expression of T-bet did not
turn out as well as we had hoped. The absorbance graphs appeared to be flat, indicating that the
ELISA was not performed properly. This error might be due to the samples themselves, however
there are multiple points in the protocol where an error could have been made. For example, the
dilution may have not been made properly, or there could have been a mistake made when
transferring from the dilution plate to the ELISA plate. There also may have been an issue with
the reagents, in that they were left out too long before performing the assay. Another possible
source of error could be that the plates were allowed to develop for too long, so the differences
between the dilutions were lost. Thus, this experiment should be repeated taking the
abovementioned sources of error into consideration. The future experiment should also explore
the other side of T-bet dependence by eliminating T-bet in all B cells and making expression of
T-bet in T cells the independent variable.
Regarding the assay used for this study, the ELISA has multiple pros and cons. The
ELISA does offer a high degree of specificity and sensitivity. However, the ELISA is limited in
that it is dependent on the amount of antibody and the interactions that form between them. If
there is a small amount of antibody or the proteins dry up, the results will be flawed. Another
issue comes from the dilutions made, if the dilution was too wide, the actual endpoint might fall
between two dilutions and thus give a false number for the endpoint. Another potential source of
error seen with this experiment was an increase in absorbance at the end of the plate where the
dilution was the highest. This was a consistent error in the ELISA data, but it does not severely
impact the data, as the endpoint titer was often achieved before the absorbance values began to
increase.
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This study was meant to serve as an introduction to T-bet and an immune response
against IAV. This study demonstrated that T-bet does impact the levels of IgG2a but there was no
clear conclusion of where the expression of T-bet is most significant in the antibody response
against IAV. Pairing this information with the literature that asserts that IgG2a is important for
protection against IAV [12], in the context of vaccination, this means we should be exploring
vaccines that illicit a greater production of IgG2a, and T-bet could be a vector to achieve this.
Now that we understand the role T-bet plays with antibody production in an IAV setting, future
studies should explore how manipulating expression of T-bet can increase the amount of class
switching to IgG2a. This would allow us to produce a more effective vaccine against IAV. These
findings are not limited to IAV however, if we understand what antibody subtypes offer the most
protection against a pathogen, cancer, or even autoimmune disease, the subtypes can be
manipulated through T-bet, or another transcription factor, to help the body mount the most
effective and protective response possible.
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